CN1169523C - Slow-releasing Tamoxifen citrate tablet - Google Patents
Slow-releasing Tamoxifen citrate tablet Download PDFInfo
- Publication number
- CN1169523C CN1169523C CNB021215960A CN02121596A CN1169523C CN 1169523 C CN1169523 C CN 1169523C CN B021215960 A CNB021215960 A CN B021215960A CN 02121596 A CN02121596 A CN 02121596A CN 1169523 C CN1169523 C CN 1169523C
- Authority
- CN
- China
- Prior art keywords
- slow
- tablet
- tamoxifen citrate
- releasing
- mesh sieves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000003578 releasing effect Effects 0.000 title claims abstract description 74
- 229960003454 tamoxifen citrate Drugs 0.000 title claims abstract description 68
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 title claims abstract description 68
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 33
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 16
- 239000008101 lactose Substances 0.000 claims description 16
- 235000019359 magnesium stearate Nutrition 0.000 claims description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 15
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 15
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 15
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 15
- 239000000741 silica gel Substances 0.000 claims description 15
- 229910002027 silica gel Inorganic materials 0.000 claims description 15
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 14
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 abstract description 46
- 239000000463 material Substances 0.000 abstract description 27
- 238000002360 preparation method Methods 0.000 abstract description 17
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 description 31
- 238000002156 mixing Methods 0.000 description 29
- 241000282472 Canis lupus familiaris Species 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 18
- 239000008187 granular material Substances 0.000 description 18
- 229960001603 tamoxifen Drugs 0.000 description 9
- -1 hydroxypropyl Chemical group 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000001476 alcoholic effect Effects 0.000 description 6
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 6
- 239000007779 soft material Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010013786 Dry skin Diseases 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 229920003081 Povidone K 30 Polymers 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000004925 Acrylic resin Substances 0.000 description 3
- 229920000178 Acrylic resin Polymers 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HBGPNLPABVUVKZ-POTXQNELSA-N (1r,3as,4s,5ar,5br,7r,7ar,11ar,11br,13as,13br)-4,7-dihydroxy-3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-2,3,4,5,6,7,7a,10,11,11b,12,13,13a,13b-tetradecahydro-1h-cyclopenta[a]chrysen-9-one Chemical compound C([C@@]12C)CC(=O)C(C)(C)[C@@H]1[C@H](O)C[C@]([C@]1(C)C[C@@H]3O)(C)[C@@H]2CC[C@H]1[C@@H]1[C@]3(C)CC[C@H]1C(=C)C HBGPNLPABVUVKZ-POTXQNELSA-N 0.000 description 1
- PFRGGOIBYLYVKM-UHFFFAOYSA-N 15alpha-hydroxylup-20(29)-en-3-one Natural products CC(=C)C1CCC2(C)CC(O)C3(C)C(CCC4C5(C)CCC(=O)C(C)(C)C5CCC34C)C12 PFRGGOIBYLYVKM-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- SOKRNBGSNZXYIO-UHFFFAOYSA-N Resinone Natural products CC(=C)C1CCC2(C)C(O)CC3(C)C(CCC4C5(C)CCC(=O)C(C)(C)C5CCC34C)C12 SOKRNBGSNZXYIO-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- MKYQPGPNVYRMHI-UHFFFAOYSA-N Triphenylethylene Chemical group C=1C=CC=CC=1C=C(C=1C=CC=CC=1)C1=CC=CC=C1 MKYQPGPNVYRMHI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001032 anti-candidal effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 239000002661 non steroidal estrogen Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a slowly releasing preparation of Tamoxifen citrate as a medicine for preventing tumors and a preparation method, wherein each tablet comprises 1 mg to 100 mg of Tamoxifen citrate, and the rest comprises slowly releasing materials and auxiliary materials.
Description
Technical field
The present invention relates to slow releasing preparation of a kind of antitumor drug Tamoxifen Citrate (Tamoxifen citrate) and preparation method thereof.
Background technology
Tamoxifen Citrate (Tamoxifen citrate), claiming tamoxifen again, chemistry (Z)-2-[by name is right-(1,2-diphenyl-1-butylene base) phenoxy group]-N, the citrate of N-diformazan ethylamine belongs to triphenylethylene non-steroidal estrogen antagonist series antineoplastic medicament.It by with target cell matter in competitive combination of estrogen receptor, block too high estrogen action in mammary gland tissue, minimizing estrogen is to the overstimulation of a breast duct and a matter.Therefore, can be used for the treatment of breast carcinoma.In addition; this medicine has also that antioxygen, film are regulated, anti-many drug resistance (Multi-drugResistance, MDR), Cardioprotective function, antiviral, anti-candida, to the influential multiple effects such as (can significantly reduce the level of IGF-I in the blood (Insulinlike Growth Factor I)) of insulin-like growth factor.
Can be absorbed rapidly after this medicine is oral, but plasma concentration peaking after 4-7 hour.Be respectively 4-hydroxyl TAM, nor-TAM (DMT), N-oxidation hydroxyethylation product etc. by the primary product after the metabolism in the body.It mainly with the form existence of N-demethylation-TAM (DMT), is a metabolite with 4-hydroxyl TAM in serum, and is most of by the feces discharge, discharges from urine on a small quantity.
In the dosage form that this medicine has gone on the market based on conventional tablet, has only research abroad to the implanted long-acting controlled release preparation of this medicine, see (Iinoy, Wolf DM, Langan-Fahey SM, Johnson DA, Ricchio M, Thompson ME, Jordan VC.Reversible control of oestradiol-stimulatedgrowth of MCF-7 tumors by tamoxifen in the athymic mouse.Br JCancer.1991Dec, 64 (6): 1019-24) (Gottardis MM, Ricchio ME, SatyaswaroopPG, Jordan VC.Effect of steroidal and nonsteroidal anti-estrogen on thegrowth of a tamoxifen-stimulated athymic mice.Cancer Res.1990Junl; 50 (1): 3189-92) (Jordan VC, Lababidi MK, Mirecki DM.Anti-estrogenicand anti-tumor properties of prolonged tamoxifen therapy in C3H/OUJmice.Eur J Cancer.1990,26 (6): 718-721), the report of dosage forms such as being made into electuary, ointment is arranged also.In addition, Olga Shakhova of Switzerland etc. is developing the injection of tamoxifen.At present, do not see the report of slow-releasing Tamoxifen citrate formulation development and research situation both at home and abroad.The invention provides a kind of slow-releasing Tamoxifen citrate tablet agent, this slow releasing tablet can reduce medicining times, and is easy to use.Tamoxifen is the medicine of life-time service, generally will use just onset after 6 months; Conventional tablet is taken two to three times every day, and compliance of patients is under some influence; Make slow releasing tablet and only need take once every day, owing to reduce medicining times, slow releasing tablet can improve the compliance that patient takes medicine.
Summary of the invention
The invention provides a kind of slow-releasing Tamoxifen citrate tablet agent, this slow releasing tablet is a sustained-release matrix with cellulose derivative or polyvinyl, these sustained-release matrixes can be methylcellulose, hydroxy methocel, hydroxyethyl-cellulose, hydroxypropyl cellulose, hydroxypropyl emthylcellulose, carboxymethyl cellulose, carboxyethyl cellulose, microcrystalline Cellulose, starch, polyvinylpyrrolidone, acrylic resin one or more mixing wherein, hydroxypropyl emthylcellulose (HPMC preferably, the hydrophilic colloid material), but these slow-release materials are met the water gelation and are formed gel layer, make medicine pass through gel layer and discharge gradually, thereby have slow-releasing and controlled-releasing action and high bioavailability preferably; Gel skeleton is dissolved in the body fluid after the release simultaneously, and does not have remaining framework ingredient, and better biocompatibility is arranged; Especially can keep comparatively ideal drug release rate.
Slow releasing tablet of the present invention, except that above-mentioned slow-release material, other adjuvant also has: binding agent, diluent, stabilizing agent in the prescription; Lubricant; Wetting agent.Binding agent wherein is: polyvinylpyrrolidone, hydroxypropyl emthylcellulose, starch slurry, syrup, dextrin, rubber cement, diluent is: lactose, starch, sucrose, pregelatinized Starch, dextrin, mannitol, sorbitol, calcium sulfate, microcrystalline Cellulose, fluidizer is: micropowder silica gel, Pulvis Talci, lubricant is: magnesium stearate, calcium stearate, Pulvis Talci, hydrogenated vegetable oil, Polyethylene Glycol, Stepanol MG, sodium lauryl sulphate, wetting agent is: ethanol, ethanol water, water.
Slow releasing tablet of the present invention, wherein the content of Tamoxifen Citrate is every 1mg-100mg, all the other are slow-release material and medicine acceptable carrier, sheet focuses on 50mg-1000mg, or the content of Tamoxifen Citrate counts 1-100 by weight, and slow-release material and medicine acceptable carrier are 10-385.
The present invention preferably fills a prescription and is (per 1000 slow-releasing Tamoxifen citrate tablets contain)
Tamoxifen Citrate 1g-100g
Hydroxypropyl methylcellulose (HPMC K4M) 3g-90g
Polyvinylpyrrolidone (PVP K30) 1g-100g
Lactose 5g-85g
Micropowder silica gel 1g-100g
Magnesium stearate 0.1g-10g
80% ethanol water is an amount of
Most preferred prescription is (per 1000 slow-releasing Tamoxifen citrate tablets contain)
Tamoxifen Citrate 15.2g
Hydroxypropyl methylcellulose 3g-90g
Polyvinylpyrrolidone 1g-100g
Lactose 5g-85g
Micropowder silica gel 1g-100g
Magnesium stearate 0.1g-10g
Slow releasing tablet of the present invention can be used the wet granule compression tablet manufactured,
Technological process is
One. the pre-treatment of adjuvant:
Tamoxifen Citrate, micropowder silica gel, magnesium stearate--〉are crossed 100 mesh sieves respectively--〉and standby
Other adjuvant--〉is crossed 80 mesh sieves respectively--〉and standby
Dehydrated alcohol--〉adds the alcoholic solution of proper amount of deionized water--〉80%--〉and standby
Two. the preparation of slow-releasing Tamoxifen citrate tablet:
1. particulate preparation:
(1) cellulose derivative and polyvinylpyrrolidone are crossed three abundant mixings of 40 mesh sieves.
(2) Tamoxifen Citrate is mixed with the equivalent method of progressively increasing with the material elder generation in (1), after three abundant mixings of 40 mesh sieves.
(3) lactose and the material in (2) are crossed three abundant mixings of 40 mesh sieves.
(4) micropowder silica gel and the material in (3) are crossed three abundant mixings of 40 mesh sieves.
(5) add 80% an amount of alcoholic solution in the material of above-mentioned mix homogeneously, mix homogeneously prepares soft material, crosses 18 mesh sieves and granulates, rapidly at 45-55 ℃ of dry 1-2 hour.
2. granulate tabletting:
Dried granules is crossed 20 mesh sieve granulate, adds the magnesium stearate of recipe quantity, and fully mixing is measured content, and it is heavy to calculate sheet, tabletting.
Slow releasing tablet of the present invention, release in sustainable 12 hours, its drug release process meets zero order kinetics.By investigation to the stability of slow releasing tablet.The result confirms that the stability of principal agent Tamoxifen Citrate is better in the slow-releasing Tamoxifen citrate tablet, and content there is no obvious variation under different experiment conditions; The catabolite inspection meets the requirements; Drug release rate does not have significance to change.In 40 ℃, placed three months down, and at room temperature placed 6 months by relative humidity 75% experiment condition under the commercially available back condition for slow-releasing Tamoxifen citrate tablet, and stability is all better, and outward appearance, hardness, drug content and release etc. there is no obvious variation.Slow-releasing Tamoxifen citrate tablet is tested in intravital pharmacokinetics of beasle dog and relative bioavailability.Article four, beasle dog intersects single oral dose test preparation (slow-releasing Tamoxifen citrate tablet) and reference preparation (Tamoxifen Citrate ordinary tablet), measures pharmacokinetics and relative bioavailability behind the single-dose; Article six, beasle dog intersection successive administration is 8 days, stable state pharmacokinetics behind the mensuration multiple dosing.Blood drug level with different time after the administration of LC/MS-MS analytical method mensuration.The result shows, four beasle dogs intersect behind single oral dose test preparation and the reference preparation, and the Tmax of slow releasing tablet significantly is longer than ordinary tablet, and the peak concentration Cmax of slow releasing tablet is starkly lower than ordinary tablet, and the relative bioavailability of slow releasing tablet is 82.7%; Article six, 8 days stable state pharmacokinetic of beasle dog intersection successive administration shows that blood drug level reached surely substantially in the 5th day, and the Tmax of slow releasing tablet also significantly is longer than ordinary tablet; Result of study confirms, no matter single or multiple administration, and slow releasing tablet reaches the peak and all obviously postpones, and the blood drug level peak steadily and broadening demonstrates the feature of slow release, and the relative bioavailability of slow releasing tablet＞80%.
Below be experimental example of the present invention, have good slow release effect and effect in order to prove slow releasing tablet of the present invention.
Experimental example
Compare the bioavailability that beasle dog is taken slow-releasing Tamoxifen citrate tablet and Tamoxifen Citrate ordinary tablet, the relative bioavailability of assessment slow-releasing Tamoxifen citrate tablet, and the experiment of the slow release dynamic characteristic of definite slow-releasing Tamoxifen citrate tablet.
Animal subject
Beasle dog
Dosage: slow-releasing Tamoxifen citrate tablet 20mg/2 sheet/dog;
Tamoxifen Citrate ordinary tablet 20mg/2 sheet/dog.
Fasting 12h before the animal subject administration, second day non-irrigated morning 7:20 once oral slow-releasing Tamoxifen citrate tablet 20mg/2 sheet or Tamoxifen Citrate ordinary tablet 20gm/2 sheet.With hands the dog mouth is broken into two with one's hands, clamped tablet with long Nie Zi and be put into the throat mouth, use the 10ml mixing in water for oral taking, the dog mouth both hands that close are fast then held the dog head are steeved, and it is the administration success that observation is swallowed down.
Do not swallow down and spue as tablet, this dog temporarily can not be used, and be used further to test after must raising for 2 weeks.The back 2h that takes medicine can feed water and drink, but the 3h feeding of taking medicine.
One. the single dose administration test
The serum drug level dynamic change
Article four, the blood drug level of different time is listed in table 1 and 2 behind beasle dog single oral (20mg) slow releasing tablet and the ordinary tablet.During by measurement result and medicine curve as seen, blood drug level rises slowly after the slow-releasing Tamoxifen citrate tablet administration, concentration change is steady, 3-5h peaking after the administration, 2-8h blood drug level maintains 65-40ng.ml after the administration
-1Scope; The Tamoxifen Citrate ordinary tablet absorbs very fast, 1-2h blood drug level peaking after the administration, and its peak concentration is higher 1 times than slow release agreement that contracts a film or TV play to an actor or actress, and the blood drug level of 5-8h then is lower than slow releasing tablet after the administration.Significantly greater than ordinary tablet (P＜0.05), the blood drug level of two kinds of preparations of 12-36h is close after the administration for the peak time of slow releasing tablet.
Table 1 beasle dog single oral slow-releasing Tamoxifen citrate tablet (20mg) concentration
Blood drug level (ng.ml
-1)
Time
(h) №1 №2 №3 №4 X+SD
0.25 0 0 0 0 0
0.5 0 0 1.4 0 0.4±0.7
1 5.5 5.8 29.8 11.9 13.3±11.4
2 22.5 85.9 60.4 89.5 64.6±30.9
3 65.5 145.0 107.3 134.6 113.1±35.5
4 79.1 77.5 119.5 129.3 101.4±26.9
5 96.4 55.6 72.5 81.3 76.5±17.0
6 76.6 47.9 77.5 60.0 65.5±14.2
7 45.5 32.0 50.7 47.4 43.9±8.2
8 32.9 38.2 52.8 34.1 39.5±9.2
12 14.7 20.7 18.3 12.2 16.5±3.8
24 1.7 10.4 6.6 11.5 7.6±4.4
36 1.3 2.4 1.3 2.1 1.8±0.6
Table 2 beasle dog single oral Tamoxifen Citrate ordinary tablet (20mg) concentration
Blood drug level (ng.ml
-1)
Time
(h) №1 №2 №3 №4 X+SD
0.25 29.3 29.5 20.8 45.4 31.3±10.3
0.5 39.4 120.1 1.9 111.3 68.2±57.1
1 195.6 229.0 38.1 220.8 170.9±89.7
2 167.0 186.1 206.7 179.6 184.9±16.6
3 107.9 138.8 168.8 160.9 144.1±27.3
4 45.1 63.3 66.4 57.6 58.1±9.4
5 46.1 47.7 58.7 34.5 46.8±9.9
6 28.1 45.7 56.1 49.1 44.8±11.9
7 34.1 47.8 37.2 24.3 35.9±9.7
8 20.0 37.4 44.0 16.4 29.5±13.3
12 12.0 11.0 7.3 9.2 9.9±2.1
24 1.7 10.4 6.6 11.5 7.6±4.4
36 3.1 2.3 1.8 1.7 2.2±0.6
Slow releasing tablet is to the relative bioavailability of ordinary tablet
Take the AUC of slow releasing tablet and ordinary tablet by every beasle dog intersection
0-36The relative bioavailability that calculates every beasle dog is listed in the table 3.The result shows that the relative bioavailability of the relative ordinary tablet of slow releasing tablet is 82 ± 11.2%, and the relative bioavailability of slow releasing preparation reaches and can be qualified preparation more than 80%.
The relative bioavailability of table 3 slow-releasing Tamoxifen citrate tablet
Animal AUC
0-36(ng.h.ml
-1) relative bioavailability
(№)
Ordinary tablet slow releasing tablet (%)
1 904.4 617.9 68.3
2 1070.2 848.9 79.3
3 965.3 876.3 90.8
4 960.0 884.7 92.2
X 975.0 807.0 82.7
SD 69.2 127.0 11.2
Two. the multiple dose administration test
Paddy concentration change during stable state
Article six, beasle dog (7:20) blood-sample withdrawal when successive administration administration in the 5th, 6,7,8 days data of measuring slow releasing tablet and ordinary tablet paddy concentration are listed in the table 4.Average paddy concentration one time graph is seen Fig. 5.Data as seen from table, multiple dose administration blood drug level of ordinary tablet and slow releasing tablet when taking medicine in the 5th day has all reached stable state, shows that absorption, distribution, the elimination curve of measuring Tamoxifen Citrate after administration in the 8th day carry out after the Tamoxifen Citrate drug level reaches stable state.The paddy concentration of two kinds of preparations when stable state is all lower.
Paddy concentration behind repeatedly oral slow-releasing Tamoxifen citrate tablet of table 4 beasle dog and the ordinary tablet
Animal paddy concentration (ng.ml
-1)
(№)
The slow releasing tablet ordinary tablet
The 5th day the 6th day the 7th day the 8th day the 5th day the 6th day the 7th day the 8th day
1 6.9 12.5 7.4 10.1 14.7 9.1 10.4 13.4
2 1.8 2.7 4.4 3.3 6.8 6.2 6.3 8.9
3 2.3 0.8 0.3 2.3 9.8 9.3 7.8 11.9
4 3.9 7.1 8.4 12.8 7.0 11.4 8.6 8.1
5 4.9 1.9 3.7 4.5 4.1 5.7 5.6 8.2
6 3.0 3.5 1.3 2.4 3.3 6.0 3.3 5.4
X 3.8 4.8 4.3 5.9 7.6 8.0 7.0 9.3
SD 1.9 4.4 2.2 4.5 4.2 2.3 2.5 2.9
Serum drug level dynamic change after the stable state
Article six, beasle dog continuous oral slow-releasing Tamoxifen citrate tablet and Tamoxifen Citrate ordinary tablet after 8 days different time blood drug level change and to see Table 5 and 6.Oral ordinary tablet of beasle dog and slow releasing tablet reach after the stable state, and blood drug level variation tendency and single-dose after the last administration in the 8th day are close.The T of slow releasing tablet
MaxBetween 3 ~ 6h, ordinary tablet T
MaxBetween 1-3h.The blood drug level of two kinds of preparations of 24h all drops to the 1/10-1/20 of peak value after the administration.36-48h blood drug level is lower after the administration, part animal blood drug level below detectability, so the 48h measurement result not with calculating.
The blood drug level of the repeatedly oral slow-releasing Tamoxifen citrate tablet of table 5 beasle dog after the 8th day
Time blood drug level (ng.ml
-1)
(h)
№1 №2 №3 №4 №5 №6 X±SD
0 10.1 3.3 2.3 12.8 4.5 2.4 5.9±4.5
0.25 12.3 4.5 6.8 11.0 4.8 2.4 7.0±3.9
0.5 10.4 3.2 15.3 12.4 4.0 2.7 8.0±5.4
1 8.6 4.1 52.0 18.9 12.0 2.2 16.3±18.5
2 14.9 10.6 50.1 44.9 39.8 2.0 27.1±20.3
3 28.2 26.6 52.0 130.6 174.1 5.6 69.5±67.2
4 32.5 51.5 28.1 129.3 116.3 12.5 61.7±49.1
5 88.4 53.3 15.5 108.5 95.7 18.2 63.3±40.4
6 52.6 27.9 15.3 92.9 129.4 78.9 66.2±42.7
7 51.3 27.5 9.8 68.2 76.6 37.2 45.1±25.2
8 50.8 36.5 6.2 47.5 50.3 48.8 40.0±17.4
12 30.2 11.5 6.5 22.3 18.6 19.3 18.1±8.3
24 4.8 3.7 2.3 15.2 8.7 3.5 6.4±4.9
36 2.9 0 0 3.3 1.4 0 1.3±1.5
The blood drug level of the repeatedly oral Tamoxifen Citrate ordinary tablet of table 6 beasle dog after the 8th day
Time blood drug level (ng.ml
-1)
(h)
№1 №2 №3 №4 №5 №6 X±SD
0 13.4 8.9 11.9 8.1 8.2 5.4 9.3±2.9
0.25 19.0 12.0 8.3 11.6 8.3 3.8 10.5±5.1
0.5 16.4 8.1 16.7 18.4 15.9 6.1 13.6±5.1
1 18.4 9.6 22.1 18.6 62.7 25.5 26.2±18.7
2 54.9 59.0 29.8 81.8 39.1 46.4 51.8±18.1
3 83.7 94.8 30.7 42.7 48.9 38.6 56.6±26.2
4 50.4 39.9 23.3 36.0 30.8 26.5 34.5±9.9
5 59.7 29.7 22.0 42.7 17.6 16.6 31.4±16.9
6 44.8 20.1 16.9 42.2 17.1 13.6 25.8±13.9
7 37.7 12.1 15.7 36.2 9.7 15.2 21.1±12.5
8 30.6 14.9 14.4 32.3 7.2 11.5 18.5±10.4
12 16.1 7.7 8.1 16.0 7.7 3.7 9.9±5.0
24 6.7 1.2 0 4.4 1.4 1.0 2.5±2.6
36 3.2 0 0 3.8 0 0 1.2±1.8
The stable state pharmacokinetic parameter
The major impetus mathematic(al) parameter of steady plasma-drug concentration data computation is listed in table 7 and 8 behind slow releasing tablet and the ordinary tablet multiple dosing.Peak-to-valley ratio (R) when reaching stable state behind two kinds of preparation multiple dosings, peak valley fluctuation degree (DF) and average blood drug level parameters such as (Cavg) are relatively listed in the table 9.The result shows the C after two kinds of preparations reach stable state
Max, C
MinAnd C
AvgThere are no significant, and difference is showed; No matter single-dose still is the T of multiple dosing to slow releasing tablet
MaxAll postpone than ordinary tablet; Steady and the broadening of C demonstrates slow releasing function.Peak-to-valley ratio (R) and peak valley fluctuation degree (DF) slow releasing tablet are all big than ordinary tablet, and significant difference (P＜0.05) is analysed in credit by statistics.
The stability kinetics parameter of the repeatedly oral slow-releasing Tamoxifen sheet of table 7 beasle dog after the 8th day
Animal T
MAXC
MAX* C
MIN* C
AvgAUC
0-36R DF
(№) (h) (ng.ml
-1) (ng.ml
-1) (ng.ml
-1) (ng.h.ml
-1)?(Cmax/Cmin) (％)
1 5 88.4 10.1 28.3 726.5 8.75 258.4
2 5 53.3 3.3 17.0 431.0 16.15 277.8
3 3 52.0 2.3 12.5 312.5 22.61 382.3
4 3 130.6 12.8 41.1 1097.2 10.20 257.8
5 3 174.1 4.5 40.5 1031.7 38.69 394.4
6 6 78.9 2.4 19.0 476.5 32.88 384.4
X 4.2 96.2 5.9 26.4 679.2 21.55 325.8
SD 1.3 47.8 4.5 12.3 328.1 12.21 67.5
Annotate: * C
MinSurveyed paddy concentration during by administration 0 in the 8th day
* C
AVG=AUC
0-36/ τ, τ=24h in the formula
The stability kinetics parameter of the repeatedly oral tamoxifen ordinary tablet of table 8 beasle dog after the 8th day
Animal T
MAXC
MAX* C
MIN* C
AvgAUC
0-36R DF
(№) (h) (ng.ml
-1) (ng.ml
-1) (ng.ml
-1)?(ng.h.ml
-1)?(Cmax/Cmin) (％)
1 3 83.7 13.4 38.9 466.6 6.25 127.4
2 3 94.8 8.9 26.9 322.2 10.65 319.3
3 3 30.7 11.9 18.1 265.8 2.58 103.9
4 2 81.8 8.1 34.9 590.6 10.10 211.2
5 1 62.7 8.2 21.1 324.3 7.65 258.3
6 2 46.4 5.4 18.0 250.5 8.59 227.8
X 2.3 66.7 9.3 26.3 112.9 7.64 216.9
SD 0.8 24.6 2.9 8.9 173.6 2.95 72.7
Annotate: * C
MinSurveyed paddy concentration during by administration 0 in the 8th day
* C
Avg=AUC
0-36/ τ, τ=12h in the formula
Table 9 slow-releasing Tamoxifen sheet and ordinary tablet stable state pharmacokinetic parameter are relatively
Kinetic parameter ordinary tablet slow releasing tablet P value
T
MAC(h) 2.3±0.8 4.2±1.3 0.0197
C
max(ng.ml
1) 66.7±47.8 96.2±47.8 0.2124
C
min(ng.ml
1) 9.3±2.9 5.9±4.5 0.1333
C
max(ng.ml
1) 26.3±8.9 26.4±12.3 0.9865
R(C
max/C
min) 7.64±2.95 21.55±12.21 0.0457
DF(％) 216.9±72.7 346.0±66.7 0.0325
N＝6， X±SD
Slow-releasing Tamoxifen citrate tablet of the present invention has the rate of release equilibrium, production technology is simple, with low cost, easy to use, Tamoxifen Citrate is an anti-breast cancer medicines commonly used clinically simultaneously, slow releasing tablet of the present invention can be provided convenience for numerous patients that suffer from breast cancer, practical, effect good quality production, has obvious social and economic benefit.
The specific embodiment:
The present invention will be further described by the following examples.
Embodiment 1
Prescription (per 1000 slow-releasing Tamoxifen citrate tablets contain)
Tamoxifen Citrate 100g
Hydroxypropyl methylcellulose (HPMC K4M) 90g
Polyvinylpyrrolidone (PVP K30) 100g
Lactose 85g
Micropowder silica gel 100g
Magnesium stearate 10g
80% ethanol water is an amount of
(1) hydroxypropyl emthylcellulose and the polyvinylpyrrolidone of recipe quantity are crossed three abundant mixings of 40 mesh sieves.
(2) Tamoxifen Citrate is mixed with the equivalent method of progressively increasing with the material elder generation in (1), after three abundant mixings of 40 mesh sieves.
(3) lactose and the material in (2) are crossed three abundant mixings of 40 mesh sieves.
(4) micropowder silica gel and the material in (3) are crossed three abundant mixings of 40 mesh sieves.
(5) add 80% an amount of alcoholic solution in the material of above-mentioned mix homogeneously, mix homogeneously prepares soft material, crosses 18 mesh sieves and granulates, rapidly 55 ℃ of dryings 2 hours.
Dried granules is crossed 20 mesh sieve granulate, adds the magnesium stearate of recipe quantity, and fully mixing is measured content, and it is heavy to calculate sheet, tabletting.
Embodiment 2
Prescription (per 1000 slow-releasing Tamoxifen citrate tablets contain)
Tamoxifen Citrate 1g
Hydroxypropyl methylcellulose (HPMC K4M) 3g
Polyvinylpyrrolidone (PVP K30) 1g
Lactose 5g
Micropowder silica gel 1g
Magnesium stearate 0.1g
80% ethanol water is an amount of
(1) hydroxypropyl emthylcellulose and the polyvinylpyrrolidone of recipe quantity are crossed three abundant mixings of 40 mesh sieves.
(2) Tamoxifen Citrate is mixed with the equivalent method of progressively increasing with the material elder generation in (1), after three abundant mixings of 40 mesh sieves.
(3) lactose and the material in (2) are crossed three abundant mixings of 40 mesh sieves.
(4) micropowder silica gel and the material in (3) are crossed three abundant mixings of 40 mesh sieves.
(5) add 80% an amount of alcoholic solution in the material of above-mentioned mix homogeneously, mix homogeneously prepares soft material, crosses 18 mesh sieves and granulates, rapidly 55 ℃ of dryings 2 hours.
Dried granules is crossed 20 mesh sieve granulate, adds the magnesium stearate of recipe quantity, and fully mixing is measured content, and it is heavy to calculate sheet, tabletting.
Embodiment 3
Prescription (per 1000 slow-releasing Tamoxifen citrate tablets contain)
Tamoxifen Citrate 50g
Hydroxypropyl methylcellulose (HPMC K4M) 45g
Polyvinylpyrrolidone (PVP K30) 50g
Lactose 42g
Micropowder silica gel 50g
Magnesium stearate 5g
80% ethanol water is an amount of
(1) hydroxypropyl emthylcellulose and the polyvinylpyrrolidone of recipe quantity are crossed three abundant mixings of 40 mesh sieves.
(2) Tamoxifen Citrate is mixed with the equivalent method of progressively increasing with the material elder generation in (1), after three abundant mixings of 40 mesh sieves.
(3) lactose and the material in (2) are crossed three abundant mixings of 40 mesh sieves.
(4) micropowder silica gel and the material in (3) are crossed three abundant mixings of 40 mesh sieves.
(5) add 80% an amount of alcoholic solution in the material of above-mentioned mix homogeneously, mix homogeneously prepares soft material, crosses 18 mesh sieves and granulates, rapidly 55 ℃ of dryings 2 hours.
Dried granules is crossed 20 mesh sieve granulate, adds the magnesium stearate of recipe quantity, and fully mixing is measured content, and it is heavy to calculate sheet, tabletting.
Embodiment 4
Prescription (per 1000 slow-releasing Tamoxifen citrate tablets contain)
Tamoxifen Citrate 100g
Acrylic resin 90g
Microcrystalline Cellulose 100g
Lactose 85g
Starch 100g
Magnesium stearate 10g
With recipe quantity Tamoxifen Citrate, acrylic resin, the abundant mixing of lactose.Starch slurry with 8% is a binding agent, and said mixture is made soft material, crosses 40 mesh sieves and makes wet granular, and rapidly 60 ℃ of dryings 1 hour, granulate adds the microcrystalline Cellulose and the magnesium stearate of recipe quantity, and fully mixing is measured content, and it is heavy to calculate sheet, tabletting.
Embodiment 5
Prescription (per 1000 slow-releasing Tamoxifen citrate tablets contain)
Tamoxifen Citrate 15.2g
Hydroxypropyl methylcellulose (HPMC K4M) 45g
Polyvinylpyrrolidone (PVP K30) 50g
Lactose 42g
Micropowder silica gel 50g
Magnesium stearate 5g
80% ethanol water is an amount of
(1) hydroxypropyl emthylcellulose and the polyvinylpyrrolidone of recipe quantity are crossed three abundant mixings of 40 mesh sieves.
(2) Tamoxifen Citrate is mixed with the equivalent method of progressively increasing with the material elder generation in (1), after three abundant mixings of 40 mesh sieves.
(3) lactose and the material in (2) are crossed three abundant mixings of 40 mesh sieves.
(4) micropowder silica gel and the material in (3) are crossed three abundant mixings of 40 mesh sieves.
(5) add 80% an amount of alcoholic solution in the material of above-mentioned mix homogeneously, mix homogeneously prepares soft material, crosses 18 mesh sieves and granulates, rapidly 55 ℃ of dryings 2 hours.
Dried granules is crossed 20 mesh sieve granulate, adds the magnesium stearate of recipe quantity, and fully mixing is measured content, and it is heavy to calculate sheet, tabletting.
Claims (2)
1. a slow-releasing Tamoxifen citrate compositions is characterized in that, per 1000 slow-releasing Tamoxifen citrate tablets contain
Tamoxifen Citrate 1g-100g
Hydroxypropyl methylcellulose 3g-90g
Polyvinylpyrrolidone 1g-100g
Lactose 5g-85g
Micropowder silica gel 1g-100g
Magnesium stearate 0.1g-10g.
2. the compositions of claim 1 is characterized in that, per 1000 slow-releasing Tamoxifen citrate tablets contain
Tamoxifen Citrate 15.2g
Hydroxypropyl methylcellulose 3g-90g
Polyvinylpyrrolidone 1g-100g
Lactose 5g-85g
Micropowder silica gel 1g-100g
Magnesium stearate 0.1g-10g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021215960A CN1169523C (en) | 2002-06-27 | 2002-06-27 | Slow-releasing Tamoxifen citrate tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021215960A CN1169523C (en) | 2002-06-27 | 2002-06-27 | Slow-releasing Tamoxifen citrate tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1389199A CN1389199A (en) | 2003-01-08 |
| CN1169523C true CN1169523C (en) | 2004-10-06 |
Family
ID=4745009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021215960A Expired - Lifetime CN1169523C (en) | 2002-06-27 | 2002-06-27 | Slow-releasing Tamoxifen citrate tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1169523C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101305985B (en) * | 2008-06-06 | 2011-12-14 | 东华大学 | Preparation method of coffee acid polylactic acid copolymer nanometer microsphere |
| CN101249082B (en) * | 2008-04-02 | 2012-03-21 | 东华大学 | Preparation of acidum citricum tamoxifen polylactic acid-glycolic co-polymer microballoons |
| CN103349650A (en) * | 2013-07-22 | 2013-10-16 | 南通广泰生化制品有限公司 | Tamoxifen citrate sustained-release tablets |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100358517C (en) * | 2004-09-28 | 2008-01-02 | 马晶 | Tamoxifen citrate oral disintegrating tablet and its preparation method |
| CN1304054C (en) * | 2004-12-29 | 2007-03-14 | 山东蓝金生物工程有限公司 | Combination of slow released anticancer medication |
| CN103494787B (en) * | 2013-07-22 | 2014-10-29 | 南通广泰生化制品有限公司 | Tamoxifen citrate dropping pill |
-
2002
- 2002-06-27 CN CNB021215960A patent/CN1169523C/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249082B (en) * | 2008-04-02 | 2012-03-21 | 东华大学 | Preparation of acidum citricum tamoxifen polylactic acid-glycolic co-polymer microballoons |
| CN101305985B (en) * | 2008-06-06 | 2011-12-14 | 东华大学 | Preparation method of coffee acid polylactic acid copolymer nanometer microsphere |
| CN103349650A (en) * | 2013-07-22 | 2013-10-16 | 南通广泰生化制品有限公司 | Tamoxifen citrate sustained-release tablets |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1389199A (en) | 2003-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1302605A (en) | Controlled releasing oral medicine composition | |
| CN1230162C (en) | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent | |
| CN1222290C (en) | Novel composition and use thereof | |
| CN1929821A (en) | Pharmaceutical composition comprising pimobendan | |
| CN1155382C (en) | Tablet with controlled release of alfuzosine chlorydrate | |
| CN1079236C (en) | tablets containing anion exchange resin | |
| CN1087262A (en) | Controlied release oxycodone compositions | |
| CN1660054A (en) | Rapidly disintegrating methylcellulose tablets | |
| CN1335767A (en) | Sustained release matrices for highly soluble drugs | |
| CN1748675A (en) | Composition of rheinic acid compounds and preparing method and use for treating diabetes | |
| CN101066251A (en) | Dispersed tablet of proton pump inhibitor | |
| CN1151794C (en) | Medicinal compositions for treating eye diseases | |
| CN1655789A (en) | New pharmaceutical compositions containing flibanserin polymorph A | |
| CN1823805A (en) | Ground erythromycin enteric micropill and its preparation method | |
| CN1169523C (en) | Slow-releasing Tamoxifen citrate tablet | |
| CN1292696A (en) | Composition | |
| CN1891218A (en) | Ranolazine hydrochloride slow-release preparation and its preparing method | |
| CN1111413C (en) | The tablet of anion exchange resin-containing | |
| CN1698594A (en) | Tiopronin slow releasing preparation | |
| CN101058568A (en) | Novel medicinal salt for cinepazide and preparation method thereof | |
| CN1150902C (en) | Prescription of preparing moxapride citrate | |
| CN1159313C (en) | Alkali-metal or alkali-earth metal salt of polyprotic acid delotadine and its medical composition | |
| CN1607943A (en) | Matrix film tablet with controlled release of a natural mixture of conjugated estrogens | |
| CN1857288A (en) | Slow released compound preparation of glycyrrhizic acid and glycyrrhizinate and its preparing process | |
| CN1222534C (en) | Form VI5,6-dichloro-2-(isopropylamino)-1-(&beta-L-ribofuranosyl)-1H-benzimidazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING CREATE FORTUNE TECHNOLOGY INDUSTRIAL GROUP Free format text: FORMER OWNER: BEIJING BEIDA PHARMACEUTICAL INDUSTRY CO., LTD. Effective date: 20110727 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100083 HAIDIAN, BEIJING TO: 100176 CHAOYANG, BEIJING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110727 Address after: 100176 Beijing city Chaoyang District sources Street No. 21 Patentee after: Beijing Chuangying Technology Industry Group Co.,Ltd. Address before: 100083 No. 38, Haidian District, Beijing, Xueyuan Road Patentee before: Beijing BeiDa Pharmaceutical Co.,Ltd. |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20030108 Assignee: BEIJING SILIAN PHARMACEUTICAL INDUSTRY Co.,Ltd. Assignor: Beijing Chuangying Technology Industry Group Co.,Ltd. Contract record no.: 2014990000963 Denomination of invention: Slow-releasing Tamoxifen citrate tablet Granted publication date: 20041006 License type: Exclusive License Record date: 20141224 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CX01 | Expiry of patent term |
Granted publication date: 20041006 |
|
| CX01 | Expiry of patent term |